The Wall Street JournalFDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood DiseaseAug 17, 2022Joseph WalkerBy Joseph Walkermore_vert
New AtlasNew $2.8-million gene therapy becomes most expensive medicine in historyAug 17, 2022Rich HaridyBy Rich Haridymore_vert
MedCity NewsBluebird Bio gene therapy wins first FDA approval for rare blood disorderAug 17, 2022Frank VinluanBy Frank Vinluanmore_vert
FiercePharmaZynteglo by BlueBird gets FDA BackingAug 17, 2022Fraiser KansteinerBy Fraiser Kansteinermore_vert
Reuters.comBluebird's $2.8 million gene therapy becomes most expensive drug after U.S. approvalAug 17, 2022Mrinalika RoyBy Mrinalika Roymore_vert
Full CoverageFull Coverage